November 11, 2026

To,
The Manager, Listing Department,
National Stock Exchange of India Limited
Exchange Plaza, C-I Block G, Bandra Kurla Complex, Bandra (East),
Mumbai-400051, Maharashtra, India

Scrip Symbol: CURIS ISIN: INE1BZN01016.

Dear Sir/Mam,

Sub.: Outcome of Board Meeting
Ref.: Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir / Madam,

In continuation to Board Meeting intimation given on 7th November, 2026, this is to inform you that in the board meeting held on 11th November, 2026 at the registered office of the company, Board has approved Unaudited Standalone and Consolidated Financial Results under AS for the half year ended on 30th September, 2026.

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the statutory auditors have carried out a "Limited Review" of the unaudited financial results for the half year ended on 30th September, 2026.

Accordingly, please find enclosed herewith a copy of the unaudited financial results along with Limited Review Report of the Company for the half year ended on 30th September, 2026.

The Board Meeting commenced at 11:00 AM and concluded at 12:15 Noon. Kindly take the same on your records.

Thanking you,

FOR CURIS LIFESCIENCES LIMITED

PATEL JAIMIK MANSUKHLAL
Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:39:18 +05'30'

JAIMIK MANSUKHLAL PATEL
WHOLE-TIME DIRECTOR
DIN: 07371003

B. T. VORA & CO.
Chartered Accountants

310, Interstellar, Nr. PRL Colony, Off Sindhu Bhavan Road, Thaltej, Ahmedabad - 380 059. **M.** : 9327014688, 8780635538 **E.**: btvora@hotmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS OF CURIS LIFESCIENCES LIMITED FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To,
The Board of Directors,
Curis Lifesciences Limited
PF-23, GIDC Sanand - II, Industrial Estate,
Sanand, Ahmedabad, Gujarat – 382110

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Curis Lifesciences Limited** ('the Company') for the half year ended September 30, 2026 ('the Statement'), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors at their meeting held on November 11, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 'Interim Financial Reporting' ('AS 25'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

B.T. VORA & CO. Ahmedabad FRN NO. 123652W CHARTERED ACCOUNTANTS

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, B T Vora & Co.
Chartered Accountants
FRN: 123652W



C. A. SHETH
Partner
Membership No.: **180506**
UDIN: 26180506NKYUOT8540

Place: Ahmedabad
Date: 11th November, 2026

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

Address: PF-23, GIDC Sanand - II, Industrial Estate, Sanand, Ahmedabad, Gujarat, India, 382110

UNAUDITED FINANCIAL RESULTS FOR THE HALF YEAR ON 30TH SEPTEMBER, 2026

(Rs. In Lakh except per share data)

Sr. No.	Particulars	For Half Year ended			Year ended	Year ended
		30.09.2026	31.03.2026	30.09.2025	31.03.2026	31.03.2025
		Unaudited	Audited	Unaudited	Audited	Audited
I	**Revenue from Operations**					
	Net sales or Revenue from Operations	3411.94	3271.99	2790.89	6062.88	5025.86
II	Other Income	44.86	28.03	0.12	28.15	1.23
III	**Total Income (I+II)**	**3456.80**	**3300.03**	**2791.01**	**6091.04**	**5027.08**
IV	**Expenses**					
(a)	Cost of Materials consumed	2271.62	2460.40	2061.64	4522.03	3376.85
(b)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	150.56	(476.16)	(205.90)	(682.06)	(207.22)
(c)	Purchase of Stock in Trade	0.91	348.74	2.87	351.61	17.21
(d)	Employee benefits expenses	187.41	189.87	171.87	361.74	322.31
(e)	Finance Costs	50.54	70.86	42.99	113.85	110.61
(f)	Depreciation and amortisation expenses	37.80	35.45	34.16	69.61	67.47
(g)	Other Expenses	192.09	234.99	161.63	396.61	442.29
	Total Expenses (IV)	**2890.93**	**2864.15**	**2269.25**	**5133.41**	**4129.52**
V	**Profit/(loss) before exceptional and extraordinary items and tax (III-IV)**	**565.87**	**435.88**	**521.76**	**957.63**	**897.56**
VI	Exceptional items {Prior Year Expenses/(Income)(net)}	2.37	1.47	-	1.47	(1.24)
VII	**Profit before extraordinary items and tax (V - VI)**	**563.50**	**434.40**	**521.76**	**956.16**	**898.80**
VIII	Extraordinary items	-	-	-	-	-
IX	**Profit before tax (VII- VIII)**	**563.50**	**434.40**	**521.76**	**956.16**	**898.80**
X	**Tax Expense**	**150.00**	**163.85**	**100.67**	**264.52**	**278.16**
(a)	Current tax	150.00	150.00	100.00	250.00	220.00
(b)	Current Tax Expense Relating to Prior years	0.00	13.29	0.00	13.29	3.47
(c)	Deferred Tax (Asset)/Liabilities	0.00	0.57	0.67	1.24	54.68
XI	**Profit (Loss) for the period (IX-X)**	**413.50**	**270.55**	**421.09**	**691.63**	**620.64**
XII	Paid-up Equity Share Capital (Face Value of Rs. 10 each)	808.44	808.44	593.44	808.44	593.44
XIII	Reserves excluding revaluation reserve				3927.33	1058.32
XIV	**Earning per equity share (for continuing operation)**					
	(a) Basic earnings (loss) per share from continuing and discontinued operations	5.75	4.01	7.10	10.26	10.87
	(b) Diluted earnings (loss) per share continuing and discontinued operations	5.75	4.01	7.10	10.26	10.87

Notes on Financial Results:-

1	The above Standalone financial results of the company, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 11th November, 2026. The Statutory Auditors have carried out a Limited Review of the results for the half year & year ended 30th September, 2026
2	The standalone half yearly financial results include the results for the half year ended 30.09.2026 and for the half year ended 31.03.2026 being the balancing figure between the audited figures in respect of the full year ended 31.03.2026 and unaudited figures of half year ended up to 30.09.2025.
3	This statement has been prepared in accordance with the Companies (Accounting Standards) Rules, 2021 (AS), prescribed under section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable. As per MCA Notification dated 16th February, 2015 Companies whose shares are listed on SME exchange as referred to in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulation, 2009, are exempted from the compulsory requirement of adoption of IND-AS.
4	Since the company has only one segment, i.e. Manufacturing of Pharmaceutical Products there is no separate reportable segment as required under AS 17.
5	The results for the half year ended on 30.09.2026 are available on the website of NSE Limited (URL: www.nseindia.com) and also on the company's website (URL: https://curisls.com/financial-results).
6	The company has successfully compeleted its Initial Public Offering (IPO) and the Equity shares are listed on SME Emerge Platform of NSE Limited on 14th November, 2025. The Company made its IPO of 21,50,000 equity shares of face value ₹10/- each at premium of ₹118/- per share, aggregating to ₹2752.00 lakhs. The issue is fully and over subscribed and the shares are allotted on 12th November, 2025.
7	Earnings per share have been computed in accordance with the Accounting Standard (AS) 20 “Earnings Per Share”. The Company issued Fresh IPO of 21,50,000 equity shares on 14-12-2025. Therefore, EPS for half year ended 30th September, 2026 and 31st March, 2026 half year and full year ended is calculated on weighted average method on day basis. As the Company has no dilutive instruments, basic and diluted EPS are the same. Further, EPS of half year ended of all periods is not annualised.
8	During the half-year ended September 30, 2026, the Company completed the acquisition of a 51% controlling equity stake in Uninova Lifesciences Private Limited ("ULPL") pursuant to a definitive Share Purchase Agreement ("SPA") dated March 27, 2026. The total cash consideration of INR 20,65,500/- (representing 1,53,000 equity shares) was advanced prior to March 31, 2026. The formal transfer and registration of equity shares were finalized on April 6, 2026, making ULPL a direct subsidiary of the Company with effect from that date. In the Standalone Financial Results, the transaction is recognized at cost under Non-Current Investments. Revenue and profits of the subsidiary are not integrated into the standalone performance metrics.
8	After the closure of the previous financial year, on August 13, 2026, Curis Lifesciences Limited ("the Company") completed a strategic cross-border investment by acquiring Ordinary shares equivalent to a 49.95% equity stake in Curosun Pharmaceutical Nig Ltd ("the Investee Company" / "Associate"), an entity incorporated under the laws of the Federal Republic of Nigeria. By virtue of this substantial voting interest, the Company exercises significant influence over the operating and financial policy decisions of the Investee Company, thereby classifying it as an Associate under AS 23 (Investment in Associates/Joint venture).
9	Previous year's/Period's figures have been re-grouped, re-arranged wherever considered necessary.

Date :- 11.11.2026

Place:- Ahmedabad

For, **Curis Lifesciences Limited**

PATEL JAIMIK MANSUKHLAL

Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:40:07 +05'30'

JAIMIK MANSUKHLAL PATEL

Whole-time director

Din: 07371003

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

Statement of Assets and Liabilities

Rs. In Lakhs

	Particulars	As At 31-09-2026 Unaudited	As At 31-03-2026 Audited
	EQUITY AND LIABILITIES		
	Shareholders' funds		
	(a) Share Capital	808.44	808.44
	(b) Reserves and Surplus	4340.83	3927.33
	(c) Money Received against share warrants	-	-
	Share application money pending allotments	-	-
	Non-Current liabilities		
	(a) Long-term Borrowings	559.95	557.95
	(b) Deferred Tax Liabilities/(Assets) (net)	113.34	113.34
	(c) Long-Term Provisions	8.61	4.67
	Current liabilities		
	(a) Short-term Borrowings	1317.41	1601.14
	(b) Trade Payables	527.27	818.06
	(c) Other Current Liabilities	81.32	75.69
	(d) Short-Term Provisions	395.27	245.46
	Total	**8152.44**	**8152.07**
	ASSETS		
	Non-Current Assets		
	(a) Property, Plant & Equipments		
	(i) Tangible Assets	1082.29	1077.71
	(ii) Capital Work In Progress	346.73	132.74
	(b) Non-Current Investments	26.16	0.50
	(c) Other Non Current Assets	27.07	27.07
	Current Assets		
	(a) Inventories	3430.85	3410.88
	(b) Trade Receivables	1450.13	1122.26
	(c) Cash and Cash Equivalents	18.60	316.51
	(d) Short-term Loans and Advances	1770.62	2064.40
	Total	**8152.44**	**8152.07**

-

Date :- 11.11.2026

Place:- Ahmedabad

For, **Curis Lifesciences Limited**

PATEL JAIMIK MANSUKHLAL

Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:40:32 +05'30'

JAIMIK MANSUKHLAL PATEL

Whole-time director

Din: 07371003

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. In Lakhs)

Particulars	For the year ended 30 September, 2026		For the year ended 31 March, 2026	
A. Cash flow from operating activities				
Net Profit / (Loss) before extraordinary items and tax		**563.50**		**956.16**
Adjustments for:				
Depreciation and amortisation	37.80		69.61	
Finance Costs	50.54		113.85	
Interest Income on Investment & Advances	(39.51)		(23.56)	
Dividend Income	(0.12)		(0.12)	
Prior Period Adjustments	(2.37)		(1.47)	
(Profit)/Loss on Sale of Assets	-		(0.88)	
Foreign Exchange Fluction Loss/(Gain)	(0.22)		(0.07)	
		46.12		**157.43**
Operating profit / (loss) before working capital changes		**609.62**		**1113.59**
Changes in working capital:				
Adjustments for (increase) / decrease in operating assets:				
Inventories	(19.97)		(1570.90)	
Trade Receivables	(327.87)		(363.85)	
Short-term loans and advances	296.18		(1557.82)	
Sub Total (a)	**(51.66)**		**(3492.58)**	
Adjustments for increase / (decrease) in operating liabilities:				
Trade payables	(290.79)		218.08	
Other current liabilities	5.63		(43.09)	
Short-term Borrowings	(283.73)		789.23	
Short Term Provisions	(0.18)		0.11	
Long term Provisions	3.94		(2.15)	
Sub Total (b)	**(565.13)**		**962.18**	
Sub Total (a+b)		**(616.79)**		**(2530.40)**
		(7.17)		**(1416.82)**
Cash flow from exceptional items				
Prior Period Adjustment(Net)	2.37		1.47	
Income Tax (Paid)/Received (net of refund)	(0.02)		(226.18)	
Sub- Total		**2.35**		**(224.71)**
Net cash flow from / (used in) operating activities (A)		**(4.81)**		**(1641.53)**

Particulars	For the year ended 30 September, 2026		For the year ended 31 March, 2026	
B. Cash flow from investing activities				
Capital expenditure on fixed assets, including capital advances		(258.60)		(180.19)
Interest Income on Investment & Advances	39.51		23.56	
Dividend Income	0.12		0.12	
Proceeds from Sale of assets	-		2.00	
Proceeds from Non Current Assets	-		(4.34)	
Investment in Equity Share of Subsidiary - Uninova Lifesciences Private Limited	(20.66)			
Investment in Equity share of Associates - Curosun Pharmaceuticals Nig Ltd	(5.00)			
		13.98		21.34
Net cash flow from / (used in) investing activities (B)		**(244.63)**		**(158.86)**

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. In Lakhs)

Particulars	For the year ended 30 September, 2026		For the year ended 31 March, 2026	
C. Cash flow from financing activities				
(Repayment)/Proceeds of Long Term Borrowings	2.00		(191.91)	
Issue of Share Capital incl. securities premium (net of expenses)	-		2392.37	
Interest Paid	(50.54)		(113.85)	
		(48.54)		2086.61
Net cash flow from / (used in) financing activities (C)		**(48.54)**		**2086.61**

Net increase / (decrease) in Cash and cash equivalents (A+B+C)		**(297.98)**		**286.23**
Cash and cash equivalents at the beginning of the year		316.58		30.36
Effect of exchange differences on restatement of foreign currency Cash and cash equivalents				
Cash and cash equivalents at the end of the year		**18.60**		**316.58**
Comprises:				
(a) Cash on hand		13.76		24.75
(b) Balances with banks				
(i) In current accounts		4.84		291.77
Gross Totals		**18.60**		**316.51**

Notes :

1) The above Cash Flow Statement has been prepared under 'Indirect Method' as set out in the Accounting Standard on 'Cash Flow Statement (AS-3)' issued by Companies (Accounting Standards) Rules,2006.

2) Previous year's figures have been rearranged/regroupped wherever necessary.

Date :- 11.11.2026
Place:- Ahmedabad

For, Curis Lifesciences Limited

PATEL JAIMIK MANSUKHLAL

Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:40:58 +05'30'

JAIMIK MANSUKHLAL PATEL
Whole-time director
Din: 07371003

B. T. VORA & CO.
Chartered Accountants

310, Interstellar, Nr. PRL Colony, Off Sindhu Bhavan Road, Thaltej, Ahmedabad - 380 059. **M.** : 9327014688, 8780635538 **E.**: btvora@hotmail.com

INDEPENDENT AUDITOR'S REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF CURIS LIFESCIENCES LIMITED FOR THE HALF YEAR ENDED SEPTEMBER 30, 2026 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED

To,
The Board of Directors,
Curis Lifesciences Limited
PF-23, GIDC Sanand - II, Industrial Estate,
Sanand, Ahmedabad, Gujarat – 382110

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Curis Lifesciences Limited** ('the Holding Company') and its subsidiary (the Holding Company and its subsidiary together referred to as 'the Group'), and its share of the net loss after tax of its associate for the half year ended September 30, 2026 ('the Statement'), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('the Listing Regulations').

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors at their meeting held on November 11, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 'Interim Financial Reporting' ('AS 25'), prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with relevant rules issued thereunder and other recognized accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

B. T. VORA & CO. Ahmedabad FR.NO. 123552W CHARTERED ACCOUNTANTS

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

Holding Company: Curis Lifesciences Limited

Subsidiary: Uninova Lifesciences Private Limited (51% equity holding, acquired effective April 6, 2026)

Associate: Curosun Pharmaceutical Nig Limited, Nigeria (49.95% equity holding, acquired effective August 13, 2026)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other recognized accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. Other Matters:

We did not review the interim financial results of **Uninova Lifesciences Private Limited**, a subsidiary included in the unaudited consolidated financial results, whose interim financial results reflect total assets of **₹298.36 Lakhs** as at September 30, 2026, total revenues of **₹320.31 Lakhs**, total net profit after tax of **₹1.16 Lakhs**, and net cash outflows of **₹0.37 Lakhs** for the half year ended September 30, 2026, as considered in the unaudited consolidated financial results. These interim financial results have been reviewed by another independent auditor, whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above.

The unaudited consolidated financial results also include the Group's share of net loss after tax of **₹0.11 Lakhs** for the half year ended September 30, 2026, as considered in the unaudited consolidated financial results, in respect of **Curosun Pharmaceutical Nig Limited** (incorporated in Nigeria), an associate, based on its interim financial information which has not been reviewed by its auditors. These unaudited interim financial information have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on such management-certified interim financial information. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.



Attention is drawn to Note 5 of the Statement, which states that as this is the first period for which consolidated financial results are prepared pursuant to the acquisitions completed during FY 2026-27, the comparative figures presented for the corresponding periods are those of the Holding Company on a standalone basis and are therefore not strictly comparable.

Our conclusion on the Statement is not modified in respect of the above matters.

For, B T Vora & Co.
Chartered Accountants
Firm Registration No.: **123652W**



C. A. SHETH
Partner
Membership No.: **180506**
UDIN: 26180506SLNEMP9581

Place: Ahmedabad
Date: 11th November, 2026

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

Address: PF-23, GIDC Sanand - II, Industrial Estate, Sanand, Ahmedabad, Gujarat, India

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026

(Rs. In Lakh except per share data)

Sr. No.	Particulars	For Half Year ended			Year ended	Year ended
		30.09.2026	31.03.2026	30.09.2025	31.03.2026	31.03.2025
		Unaudited - Consolidated	Audited - Standalone*	Unaudited - Standalone*	Audited - Standalone*	Audited - Standalone*
I	**Revenue from Operations**					
	Net sales or Revenue from Operations	3703.39	3271.99	2790.89	6062.88	5025.86
II	Other Income	45.56	28.03	0.12	28.15	1.23
III	**Total Income (I+II)**	**3748.95**	**3300.03**	**2791.01**	**6091.04**	**5027.08**
IV	**Expenses**					
(a)	Cost of Materials consumed	2262.82	2460.40	2061.64	4522.03	3376.85
(b)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	75.56	(476.16)	(205.90)	(682.06)	(207.22)
(c)	Purchase of Stock in Trade	348.80	348.74	2.87	351.61	17.21
(d)	Employee benefits expenses	195.90	189.87	171.87	361.74	322.31
(e)	Finance Costs	56.32	70.86	42.99	113.85	110.61
(f)	Depreciation and amortisation expenses	38.72	35.45	34.16	69.61	67.47
(g)	Other Expenses	203.81	234.99	161.63	396.61	442.29
	Total Expenses (IV)	**3181.92**	**2864.15**	**2269.25**	**5133.41**	**4129.52**
V	**Profit/(loss) before exceptional and extraordinary items and tax (III-IV)**	**567.03**	**435.88**	**521.76**	**957.63**	**897.56**
VI	Exceptional items {Prior Year Expenses/(Income)(net)}	2.37	1.47	0.00	1.47	(1.24)
VII	**Profit before extraordinary items and tax (V - VI)**	**564.66**	**434.40**	**521.76**	**956.16**	**898.80**
VIII	Extraordinary items	0.00	0.00	0.00	0.00	0.00
IX	**Profit before tax (VII- VIII)**	**564.66**	**434.40**	**521.76**	**956.16**	**898.80**
X	**Tax Expense**	**150.00**	**163.85**	**100.67**	**264.52**	**278.16**
(a)	Current tax	150.00	150.00	100.00	250.00	220.00
(b)	Current Tax Expense Relating to Prior years	-	13.29	-	13.29	3.47
(c)	Deferred Tax (Asset)/Liabilities	-	0.57	0.67	1.24	54.68
XI	**Profit (Loss) for the period before share of associate and minority interest (IX-X)**	**414.66**	**270.55**	**421.09**	**691.63**	**620.64**
XII	Share of profit/(loss) of associate (Curosun Pharmaceutical Nig Ltd)	(0.11)	-	-	-	-
XIII	**Profit/(Loss) after share of associate (XI+XII)**	**414.55**	**270.55**	**421.09**	**691.63**	**620.64**
XIV	Less: Share of Minority interest	(0.57)	-	-	-	-
XV	**Profit/(Loss) attributable to owners of the Company (XIII-XIV)**	**413.98**	**270.55**	**421.09**	**691.63**	**620.64**
XVI	Paid-up Equity Share Capital (Face Value of Rs. 10 each)	808.44	808.44	593.44	808.44	593.44
XVII	Reserves excluding revaluation reserve (as per balance sheet)				3927.33	1058.32
XVIII	**Earning per equity share (for continuing operation)**					
	(a) Basic earnings (loss) per share from continuing and discontinued operations	5.76	4.01	7.10	10.26	10.87
	(b) Diluted earnings (loss) per share continuing and discontinued operations	5.76	4.01	7.10	10.26	10.87

Notes on Consolidated Financial Results:-

1	The above consolidated unaudited financial results of Curis Lifesciences Limited ("the Company"), its subsidiary and its associate have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 11th November, 2026. The Statutory Auditors have carried out a Limited Review of the results.
2	The consolidated financial results are prepared in accordance with AS 21 (Consolidated Financial Statements) and AS 23 (Accounting for Investments in Associates) of the Companies (Accounting Standards) Rules, 2021. The subsidiary is consolidated line-by-line; the associate is accounted for by the equity method.
3	Subsidiary: Uninova Lifesciences Private Limited (ULPL) - 51% (1,53,000 equity shares) acquired for Rs. 20,65,500/- share transfer registered 6th April 2026; consolidated for the half year ended 30.09.2026. Minority interest is 49%. Goodwill on consolidation arising on acquisition is shown separately in the consolidated balance sheet.
4	Associate: Curosun Pharmaceutical Nig Ltd (Nigeria) - 49.95% acquired on 13th August 2026 for Rs. 5,00,000/- (purchased from an existing shareholder). The Company's share of the associate's post-acquisition loss is recognised under AS 23 (limited to the carrying amount of the investment); the associate's Nigerian Naira accounts are translated into INR at the relevant exchange rates.
5	***As this is the first period for which consolidated results are prepared (ULPL and Curosun were acquired during FY 2026-27), comparative figures are those of the Company on a standalone basis and are not strictly comparable.**
6	Inter-company transactions (sales and purchases) and balances (loan and trade balances) between the Company and ULPL have been eliminated on consolidation.
7	Since the group has only one reportable business segment, i.e. Pharmaceutical Products, no separate segment information is required under AS 17.
8	Earnings per share have been computed in accordance with AS 20 on profit attributable to owners of the Company; basic and diluted EPS are the same as the Company has no dilutive instruments. EPS of half year ended periods is not annualised.
9	Previous year's/period's figures have been re-grouped, re-arranged wherever considered necessary.

Date :- 11.11.2026
Place:- Ahmedabad

For, Curis Lifesciences Limited

PATEL JAIMIK MANSUKHLAL

Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:41:37 +05'30'

JAIMIK MANSUKHLAL PATEL
Whole-time director
Din: 07371003

CURIS LIFESCIENCES LIMITED
(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)
CIN: L24230GJ2016PLC086559
Consolidated Statement of Assets and Liabilities

(Rs. In Lakh)

	Particulars	As at 30-09-2026 Unaudited (Consolidated)	As at 31-03-2026 Audited (Standalone)
	EQUITY AND LIABILITIES		
	Shareholders' funds		
	(a) Share Capital	808.44	808.44
	(b) Reserves and Surplus	4341.31	3927.33
	(c) Money Received against share warrants	-	-
	Minority Interest	19.31	-
	Share application money pending allotments	-	-
	Non-Current liabilities		
	(a) Long-term Borrowings	585.78	557.95
	(b) Deferred Tax Liabilities/(Assets) (net)	113.34	113.34
	(c) Long-Term Provisions	8.61	4.67
	Current liabilities		
	(a) Short-term Borrowings	1417.36	1601.14
	(b) Trade Payables	624.77	818.06
	(c) Other Current Liabilities	83.47	75.69
	(d) Short-Term Provisions	395.52	245.46
	Total	**8397.92**	**8152.07**
	ASSETS		
	Non-Current Assets		
	(a) Property, Plant & Equipments		
	(i) Tangible Assets	1096.47	1077.71
	(ii) Capital Work In Progress	346.73	132.74
	(b) Goodwill on consolidation	1.15	0.00
	(c) Non-Current Investments	5.39	0.50
	(d) Deferred Tax Assets (net)	0.36	0.00
	(e) Other Non Current Assets	50.03	27.07
	Current Assets		
	(a) Inventories	3554.87	3410.88
	(b) Trade Receivables	1560.03	1122.26
	(c) Cash and Cash Equivalents	18.63	316.51
	(d) Short-term Loans and Advances	1764.27	2064.40
	Total	**8397.92**	**8152.07**

Note: As this is the first period for which consolidated results are prepared (ULPL and Curosun were acquired during FY 2026-27), comparative figures are those of the Company on a standalone basis and are not strictly comparable.

Date :- 11.11.2026
Place:- Ahmedabad

For, Curis Lifesciences Limited

PATEL JAIMIK MANSUKHLAL
Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:41:57 +05'30'

JAIMIK MANSUKHLAL PATEL
Whole-time director
Din: 07371003

CURIS LIFESCIENCES LIMITED

(FKA: CURIS LIFESCIENCES PRIVATE LIMITED)

CIN: L24230GJ2016PLC086559

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30TH SEPTEMBER, 2026

Particulars	CONSOLIDATED - UNAUDITED	STANDALONE - AUDITED
	For the period ended 30 September, 2026	For the year ended 31 March, 2026
A. Cash flow from operating activities		
Net profit before tax and extraordinary items	**564.66**	**956.16**
Adjustments for:		
Depreciation and amortisation	38.72	69.61
Finance costs	56.32	113.85
Interest income	(40.15)	(23.56)
Dividend income	(0.12)	(0.12)
Prior period adjustments	(2.37)	(1.47)
(Profit)/loss on sale of assets	-	(0.88)
Foreign exchange (gain)/loss	(0.22)	(0.07)
Operating profit before working capital changes	**616.85**	**1113.52**
Inventories	(94.98)	(1570.90)
Trade receivables	(315.34)	(363.85)
Short-term loans and advances	312.80	(1557.82)
Trade payables	(269.10)	218.08
Other current liabilities	6.23	(43.09)
Short-term borrowings	(268.60)	789.23
Short-term provisions	(11.74)	0.11
Long-term provisions	3.94	(2.15)
Prior period adjustment (net)	2.37	1.47
Income tax (paid)/received (net of refund)	(0.02)	(226.18)
Net cash flow from / (used in) operating activities (A)	**(17.59)**	**(1641.60)**
B. Cash flow from investing activities		
Capital expenditure on fixed assets incl. capital advances	(258.63)	(180.19)
Interest received	40.15	23.56
Dividend received	0.12	0.12
Proceeds from sale of assets	-	2.00
Proceeds from / (investment in) non-current assets	(0.64)	(4.34)
Acquisition of subsidiary - Uninova (net of cash acquired)	(20.25)	-
Investment in associate - Curosun Pharmaceutical Nig Ltd	(5.00)	-
Net cash flow from / (used in) investing activities (B)	**(244.25)**	**(158.86)**
C. Cash flow from financing activities		
(Repayment)/proceeds of long-term borrowings	20.22	(191.91)
Issue of share capital incl. securities premium (net of expenses)	-	2392.37
Interest paid	(56.32)	(113.85)
Net cash flow from / (used in) financing activities (C)	**(36.11)**	**2086.61**
Net increase / (decrease) in cash and cash equivalents (A+B+C)	**(297.95)**	**286.16**
Cash and cash equivalents at the beginning of the period	316.58	30.36
Cash and cash equivalents at the end of the period	**18.63**	**316.51**

Comprises:		
(a) Cash on hand	**13.79**	**24.75**
(b) Balances with banks		
(i) In current accounts	**4.85**	**291.77**
Gross Totals	**18.63**	**316.51**

Notes :

1) The above Cash Flow Statement has been prepared under 'Indirect Method' as set out in the Accounting Standard on 'Cash Flow Statement (AS-3)' issued by Companies (Accounting Standards) Rules, 2006.

2) Previous year's figures have been rearranged/regroupped wherever necessary.

3) As this is the first period for which consolidated results are prepared (ULPL and Curosun were acquired during FY 2026-27), comparative figures are those of the Company on a standalone basis and are not strictly comparable.

Date :- 11.11.2026

Place:- Ahmedabad

For, Curis Lifesciences Limited

PATEL JAIMIK MANSUKHLAL

Digitally signed by PATEL JAIMIK MANSUKHLAL
Date: 2026.11.11 12:42:19 +05'30'

JAIMIK MANSUKHLAL PATEL

Whole-time director

Din: 07371003